company background image
0YC0 logo

Unity Biotechnology LSE:0YC0 Stock Report

Last Price

US$2.66

Market Cap

US$35.2m

7D

61.2%

1Y

53.0%

Updated

23 Jan, 2025

Data

Company Financials +

Unity Biotechnology, Inc.

LSE:0YC0 Stock Report

Market Cap: US$35.2m

My Notes

Capture your thoughts, links and company narrative

Unity Biotechnology, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Unity Biotechnology
Historical stock prices
Current Share PriceUS$2.66
52 Week HighUS$3.04
52 Week LowUS$0.96
Beta0.80
1 Month Change171.70%
3 Month Change100.18%
1 Year Change53.01%
3 Year Change-76.95%
5 Year Changen/a
Change since IPO-98.14%

Recent News & Updates

Recent updates

Shareholder Returns

0YC0GB BiotechsGB Market
7D61.2%-0.2%2.5%
1Y53.0%-23.0%10.0%

Return vs Industry: 0YC0 exceeded the UK Biotechs industry which returned -23% over the past year.

Return vs Market: 0YC0 exceeded the UK Market which returned 10% over the past year.

Price Volatility

Is 0YC0's price volatile compared to industry and market?
0YC0 volatility
0YC0 Average Weekly Movement26.2%
Biotechs Industry Average Movement9.0%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.9%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0YC0's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0YC0's weekly volatility has increased from 15% to 26% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200919Anirvan Ghoshunitybiotechnology.com

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company’s lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.

Unity Biotechnology, Inc. Fundamentals Summary

How do Unity Biotechnology's earnings and revenue compare to its market cap?
0YC0 fundamental statistics
Market capUS$35.22m
Earnings (TTM)-US$21.89m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0YC0 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$18.39m
Gross Profit-US$18.39m
Other ExpensesUS$3.50m
Earnings-US$21.89m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.30
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 0YC0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 00:25
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Unity Biotechnology, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elemer PirosCantor Fitzgerald & Co.
Daniil GataulinChardan Capital Markets, LLC
Yigal NochomovitzCitigroup Inc